IP Library Granted Patent US 6,951,641
Granted Patent B2
US 6,951,641 · App. 10/821,352 · Granted Oct 4, 2005

Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,951,641
App. No.
10/821,352
Granted
Oct 4, 2005
Kind
B2
Abstract

The present application is directed to the use of X-ray contrast media that act as universal antigens that are labeled herein as “pseudoantigens.” X-ray contrast media have the potential to exist in an aggregated state that is greater in increased concentrations. In this aggregated state, contrast media assume the role of multivalent antigens and can successfully compete with any other antigens involved in antibody-antigen reactions that lead to anaphylaxis. In this competition, the large quantity of contrast media serves to inhibit the adverse effects of antibody-antigen reactions without the contrast media itself creating antibodies or creating toxicity problems.

Claims (6)

1. A method of treating allergic conjunctivitis comprising the step of administering from 0.1 to 3 ml of a dimeric nonionic X-ray contrast media selected from triiodinated, completely or partially substituted, benzene moieties existing in the form of a dimer, to an eye of a mammal suffering allergic conjunctivtis.

2. The method of claim 1 wherein the X-ray contrast media is selected from the group consisting of IOTROLAN and IODIXANOL.

3. A method of treating allergic rhinitis comprising administering from 0.1 to 3 ml of a dimeric nonionic X-ray contrast media selected from triiodinated, completely or partially substituted, benzene moieties existing in the form of a dimer, into the nose in a mammal suffering from allergic rhinitis.

4. The method of claim 3 , wherein the X-ray contrast media is selected from the group consisting of IOTROLAN and IODIXANOL.

5. The method of claim 4 , wherein the X-ray contrast media is IODIXANOL.

6. The method of claim 2 , wherein the X-ray contrast media is IODIXANOL.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2015
From: LASSER FAMILY PARTNERSHIP LLP
To: 3E THERAPEUTICS CORPORATION
Reel/Frame 034893/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2008
From: LASSER, ELLIOTT C.
To: LASSER FAMILY PARTNERSHIP, L.P.
Reel/Frame 021339/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2004
From: ALLIANCE PHARMACEUTICAL CORP
To: LASSER, ELLIOTT C.
Reel/Frame 015299/0677 →